Literature DB >> 7950525

The therapeutic use of bisphosphonates.

J E Compston1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7950525      PMCID： PMC2540833          DOI： 10.1136/bmj.309.6956.711

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  19 in total

1.  Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.

Authors:  T Storm; T Steiniche; G Thamsborg; F Melsen
Journal:  J Bone Miner Res       Date:  1993-02       Impact factor: 6.741

2.  Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.

Authors:  S Adami; M C Baroni; M Broggini; L Carratelli; I Caruso; L Gnessi; M Laurenzi; A Lombardi; G Norbiato; S Ortolani
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 3.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 4.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

5.  Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease.

Authors:  B F Boyce; L Smith; I Fogelman; E Johnston; S Ralston; I T Boyle
Journal:  Lancet       Date:  1984-04-14       Impact factor: 79.321

6.  Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss.

Authors:  H Mulder; A Struys
Journal:  Br J Rheumatol       Date:  1994-04

7.  Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

Authors:  S T Harris; N B Watts; R D Jackson; H K Genant; R D Wasnich; P Ross; P D Miller; A A Licata; C H Chesnut
Journal:  Am J Med       Date:  1993-12       Impact factor: 4.965

Review 8.  HRT and osteoporosis.

Authors:  J E Compston
Journal:  Br Med Bull       Date:  1992-04       Impact factor: 4.291

Review 9.  Clinical effects of bisphosphonates in involutional osteoporosis.

Authors:  S M Ott
Journal:  J Bone Miner Res       Date:  1993-12       Impact factor: 6.741

10.  Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.

Authors:  S J Gallacher; J A Fenner; K Anderson; F M Bryden; S W Banham; F C Logue; R A Cowan; I T Boyle
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139
View more
  10 in total

Review 1.  The role of SERMs in the management of postmenopausal osteoporosis.

Authors:  J Compston
Journal:  J Endocrinol Invest       Date:  1999-09       Impact factor: 4.256

2.  Further hearing loss during osteoporosis treatment with etidronate.

Authors:  S Yaşil; A Cömlekçi; A Güneri
Journal:  Postgrad Med J       Date:  1998-06       Impact factor: 2.401

Review 3.  Management strategies for chronic pain.

Authors:  D M Justins
Journal:  Ann Rheum Dis       Date:  1996-09       Impact factor: 19.103

4.  Therapeutic use of bisphosphonates in oncology.

Authors:  R E Coleman
Journal:  BMJ       Date:  1994-11-05

5.  Clodronate acts on human osteoclastic cell proliferation, differentiation and function in a bioreversible manner.

Authors:  Raffaella Recenti; Giuseppe Leone; Lisa Simi; Marco Orfei; Pamela Pinzani; Giuseppe Pieraccini; Gloriano Moneti; Anna Maria Carossino; Alessandro Franchi; Gianluca Bartolucci; Silvia Carbonell Sala; Mauro Ginanneschi; Annalisa Tanini; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2007-05

Review 6.  Prevention and management of osteoporosis. Current trends and future prospects.

Authors:  J E Compston
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

7.  Risedronate gastrointestinal absorption is independent of site and rate of administration.

Authors:  D Y Mitchell; R A Eusebio; L E Dunlap; K A Pallone; J D Nesbitt; D A Russell; M E Clay; P J Bekker
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

Review 8.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

9.  [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].

Authors:  J Pfeilschifter; R Ziegler
Journal:  Med Klin (Munich)       Date:  1998-06-15

10.  Bone augmentation using a new injectable bone graft substitute by combining calcium phosphate and bisphosphonate as composite--an animal model.

Authors:  Carsten W Schlickewei; Georg Laaff; Anne Andresen; Till O Klatte; Johannes M Rueger; Johannes Ruesing; Matthias Epple; Wolfgang Lehmann
Journal:  J Orthop Surg Res       Date:  2015-07-25       Impact factor: 2.359
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.